Drug Utilization Review (DUR) Meeting Minutes
December 3, 2014

Members Present: John Savageau, Jeffrey Hostetter, Peter Woodrow, Russ Sobotta, Tanya Schmidt, Steve Irsfeld, Michael Booth, Carlotta McCleary, Laura Schield, Katie Kram, Wendy Brown, Emmet Kenney

Members Absent: James Carlson, Leann Ness

Medicaid Pharmacy Department: Brendan Joyce

J. Savageau called the meeting to order at 1:00 p.m. Chair J. Savageau asked for a motion to approve the minutes from the September meeting. J. Hostetter moved that the minutes be approved, and P. Woodrow seconded the motion. Chair J. Savageau called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Updated AAP guidelines for palivizumab prophylaxis
B. Joyce discussed the updated guidelines for palivizumab (Synagis) and the Board watched the American Academy of Pediatrics webinar providing a summary of the recommendations. The Board voted to accept the updated guidelines at the September meeting and asked that data be brought back in December showing how many children during the 2013-2014 Synagis season would not have received medication. The Board reviewed the data provided. Dr. Rafeal Ocejo, a pediatrician in Bismarck, spoke regarding the new guidelines. Dr. Joan Connell, a pediatrician in Bismark, spoke regarding the new guidelines. A. Bandell, representing MedImmune, spoke regarding Synagis. A motion was made by J. Hostetter to continue using the new guidelines and include patients 29 weeks – 31weeks and 6 days gestational age. K. Kram seconded the motion. Chair J. Savageau called for a voice vote. The motion passed with no audible dissent. All PA requests that do not meet AAP guidelines will be reviewed on a case-by-case basis.

Benzodiazepine review
B. Joyce reviewed benzodiazepine utilization with the Board. Data regarding duplicate therapy, top prescribers, top diagnoses, and age ranges of patients was shared. A recommendation was made to limit duplicate benzodiazepine therapy to one short-acting product and one long-acting product. Quantity limits may also be implemented.

Second reviews
A motion and second were made at the September meeting to place topical testosterone products, phosphate binders, Zontivity, and Evzio on prior authorization. The topics were brought up for a second review. There was no public comment. After discussion, Chair J. Savageau called for a voice vote to approve the motion. The motion passed with no audible dissent.

Yearly PA review
The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. All forms and criteria were reviewed. Changes suggested:

1. Buprenorphine form-add ‘to the best of my knowledge’ at the beginning of the check box that says ‘patient is not taking other opioids, tramadol, or carisoprodol concurrently with buprenorphine containing products.’
2. Remove Cozaar from the ARB form.
3. Make sure all new products are on the COPD form.

J. Howard, representing Mylan, spoke regarding Epi-Pen.

Criteria recommendations
The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are usually consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. P. Woodrow moved to approve the new criteria and W. Brown seconded the motion. Chair J. Savageau called for a voice vote. The motion passed with no audible dissent.

The next DUR Board meeting will be held March 4 in Bismarck. J. Hostetter made a motion to adjourn the meeting. W. Brown seconded. The motion passed with no audible dissent. J. Savageau adjourned the meeting.